Is DSIP approved or regulated?

No. DSIP has never been approved as a drug in any major jurisdiction and has not gone through modern clinical development. It exists only as a research peptide with older, small human studies behind it.

What else has it been studied for?

Beyond sleep, small or uncontrolled studies looked at chronic pain and at easing opioid withdrawal, and animal work has explored stress and antioxidant effects. None of these uses is supported by robust modern trials.

Its mechanism is genuinely unclear. It has no single well-defined receptor, and proposed actions include modulating neurotransmitters and stress hormones. Even its ability to cross the blood-brain barrier and its natural role in the body remain unresolved.

There is no adequate safety data. The human studies are old, small, and short, with no long-term or modern controlled safety evaluation, so DSIP should be regarded as an unstudied research chemical of unknown risk rather than a safe therapeutic.

Research chemical — not approved

Delta sleep-inducing peptide — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Delta sleep-inducing peptide is a peptide catalogued under Cognitive & Nootropic. Neutral reference entry; EU status: not approved for human use (research use only).

What is Delta sleep-inducing peptide?

Delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s from the cerebral venous blood of sleeping rabbits, named for its early association with delta-wave (slow-wave) sleep.

It is NOT an approved drug anywhere and has never completed modern regulatory development; the human literature consists mainly of older, small studies from the 1980s-1990s in insomnia, pain, and stress/withdrawal, plus animal work.

The evidence base is weak and inconsistent: some early trials suggested benefits while other controlled trials found little or no effect, so DSIP is best characterized as a historically interesting but unproven research peptide.

How does Delta sleep-inducing peptide work?

DSIP's mechanism remains poorly understood despite decades of study; it does not have a single well-defined receptor, and proposed actions include modulation of neurotransmitter systems, stress-hormone (corticotropin/cortisol) regulation, and antioxidant or membrane-level effects.

Because its transport across the blood-brain barrier and its endogenous role are still not clearly established, its named sleep-promoting effect has never been mechanistically confirmed. [INFOGRAPHIC: DSIP proposed sleep and stress modulation]

What does the research say about Delta sleep-inducing peptide?

For insomnia, results are genuinely inconsistent: an early double-blind study reported some improvement in sleep measures, but this benefit was modest and not reliably reproduced, so DSIP cannot be considered an established sleep aid. ^[1]
In severe chronic insomnia, a controlled trial evaluating 24-hour sleep-wake behavior found that DSIP did NOT produce meaningful clinical improvement, an honest negative result that tempers the peptide's sleep reputation. ^[2]
For chronic pain, an early clinical study reported that DSIP reduced pain episodes in patients with pronounced chronic pain, but this was a small, dated study without modern controls, so the finding is preliminary at best. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study — Bes F et al., Neuropsychobiology 1992. (RCT (double-blind, small))
[2] Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Schneider-Helmert D et al., Eur Neurol 1987. (controlled clinical trial (small))
[3] Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes — Larbig W et al., Eur Neurol 1984. (small clinical study)
[4] Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial — Backmund M et al., J Clin Psychopharmacol 1998. (open-label clinical trial (uncontrolled))
[5] Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — Monti JM et al., Int J Clin Pharmacol Res 1987. (controlled clinical trial (small))
[6] Delta-sleep-inducing peptide (DSIP): a review — Graf MV et al., Neurosci Biobehav Rev 1984. (review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Historical human studies administered DSIP in roughly the 25 microgram/kg range by intravenous or subcutaneous injection over a few days, but protocols varied and were not standardized.

These historical figures are provided only for context and do not constitute a usage recommendation, given the absence of validated dosing or safety data.

Side effects & safety profile

The available human studies are small and old, and while they did not report major acute toxicity, they are inadequate to characterize the real safety profile of DSIP.

There is essentially no modern controlled safety data, no long-term data, and no pharmaceutical-grade regulatory oversight, so any use is unstudied and carries unknown risk.

It should be treated strictly as a research chemical, not a therapeutic agent.

Stacking & combinations

There is no established or evidence-based stacking protocol for DSIP; historical studies used it alone, and any combination use is purely speculative.

Finding Delta sleep-inducing peptide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

The evidence is weak and inconsistent. Some small early trials reported modest sleep improvements, but at least one controlled trial in severe chronic insomnia found no meaningful benefit, so DSIP is not an established or proven sleep aid.

References

[1] Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study — Bes F et al., Neuropsychobiology 1992. PMID: 1299794. View sourceStudy: RCT (double-blind, small)Reported limited/modest effects of DSIP on sleep in chronic insomniacs, without robust clinical benefit.
[2] Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Schneider-Helmert D et al., Eur Neurol 1987. PMID: 3622582. View sourceStudy: controlled clinical trial (small)DSIP did not produce meaningful improvement in 24-hour sleep-wake behavior in severe chronic insomnia (largely negative).
[3] Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes — Larbig W et al., Eur Neurol 1984. PMID: 6548970. View sourceStudy: small clinical studyReported reduction in chronic pain episodes with DSIP, but in a small, dated, minimally controlled setting.
[4] Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial — Backmund M et al., J Clin Psychopharmacol 1998. PMID: 9617990. View sourceStudy: open-label clinical trial (uncontrolled)Suggested DSIP might ease opioid withdrawal, but the open, uncontrolled design provides weak evidence.
[5] Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — Monti JM et al., Int J Clin Pharmacol Res 1987. PMID: 3583493. View sourceStudy: controlled clinical trial (small)Short-term DSIP administration showed some sleep improvement in chronic insomniacs, though effects were limited.
[6] Delta-sleep-inducing peptide (DSIP): a review — Graf MV et al., Neurosci Biobehav Rev 1984. PMID: 6145137. View sourceStudy: reviewReviews the isolation, proposed physiology, and unresolved mechanistic uncertainties of DSIP.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.